by Prof. Wim Vanhaverbeke Hasselt University (Belgium), ESADE Business School (Spain) [Side Event at WIPO General Assemblies on 22nd September 2010]
Read moreDr. Konji Sebati Senior Advisor, Global Issues, WIPO [Side Event at WIPO General Assemblies, on 22nd September 2010]
Read moreby Mr. Stéphane Tronchon Director IP Europe, Qualcomm [Side Event at WIPO General Assemblies on 22nd September 2010]
Read moreby Mr. Robert DeBerardine Global Head of Patents, sanofi-aventis [Side Event at WIPO General Assemblies on 22nd September 2010]
Read moreby Axel Braun Geneva Pharma Forum: on 24 November 2009
Read moreThe International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) is pleased to announce that Biogen Idec Inc. has joined the Federation, thus bringing its membership up to 29 leading international companies and 44 national and regional industry associations. IFPMA Director General Eduardo Pisani said: “We are delighted to welcome Biogen Idec, a pioneering biotech company,...
Read moreThe International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) is pleased to announce that Lundbeck and Innovative Pharma have joined the Federation, thus bringing its membership up to 28 leading international companies and 45 national and regional industry associations. Lundbeck is a global pharmaceutical company conducting research for the treatment of disorders in the central...
Read moreThe International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) is pleased to announce the addition of a new member, Otsuka Pharmaceutical Co., Ltd. (Otsuka), a subsidiary of Otsuka Holdings Co., Ltd., Japan’s second largest research-based pharmaceutical company group. Otsuka’s accession to IFPMA was approved at the Council meeting held on June 22, 2011. “Otsuka’s participation...
Read moreThe research-based pharmaceutical industry launches today a Framework for Action to respond to concerns that cardiovascular disease, cancer, diabetes and chronic respiratory diseases are posing mounting threats to public health as well as public and private finances worldwide. The industry’s ten-point Framework scopes out specific areas of action to tackle non-communicable diseases (NCDs) including innovation,...
Read moreAs one of the 189 nongovernmental organizations (NGOs) in official relations with the World Health Organization (WHO), and in line with WHO principles governing relations with NGOs, representatives of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) were present to listen to the proceedings of the 64 th World Health Assembly (WHA). The IFPMA...
Read moreIFPMA Statement, WHA 64, Item 13.12, Prevention and Control of Non Communicable Diseases Delivered by Mr Mario Ottiglio, Associate Director, Public Affairs and Global Health Policy Thank you on behalf of the International Federation of Pharmaceutical Manufacturers and Associations, the IFPMA, for the opportunity to provide our industry’s perspective on non-communicable diseases. The IFPMA represents...
Read moreIFPMA Statement under WHA 64 agenda item 13.7 Delivered by Mr Mario Ottiglio, Associate Director, Public Affairs & Global Health Policy On behalf of the International Federation of Pharmaceutical Manufacturers and Associations, the IFPMA, I thank you for the opportunity to address the issue related to fake medical products. Mr Chairman, Madame Director General, the...
Read more